These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33733667)

  • 1. Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
    Chaki S
    Int J Neuropsychopharmacol; 2021 Jul; 24(6):450-463. PubMed ID: 33733667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.
    Katz DA; Locke C; Greco N; Liu W; Tracy KA
    Brain Behav; 2017 Mar; 7(3):e00628. PubMed ID: 28293470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
    Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
    Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
    Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
    Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HPA Axis as Target for Depression.
    Menke A
    Curr Neuropharmacol; 2024; 22(5):904-915. PubMed ID: 37581323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.
    Katz DA; Liu W; Locke C; Dutta S; Tracy KA
    Psychopharmacology (Berl); 2016 Jan; 233(1):71-81. PubMed ID: 26407603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel and selective V1B receptor antagonist.
    Craighead M; Milne R; Campbell-Wan L; Watson L; Presland J; Thomson FJ; Marston HM; Macsweeney CP
    Prog Brain Res; 2008; 170():527-35. PubMed ID: 18655906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin.
    Goncharova ND; Chigarova OA; Oganyan TE
    Bull Exp Biol Med; 2018 Nov; 166(1):86-91. PubMed ID: 30450521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin in health and disease with a focus on affective disorders.
    Zelena D
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats.
    Zhou Y; Colombo G; Carai MA; Ho A; Gessa GL; Kreek MJ
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1876-83. PubMed ID: 21575018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin as a target for antidepressant development: an assessment of the available evidence.
    Scott LV; Dinan TG
    J Affect Disord; 2002 Nov; 72(2):113-24. PubMed ID: 12200202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
    Griebel G; Stemmelin J; Gal CS; Soubrié P
    Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative approaches for the treatment of depression: targeting the HPA axis.
    Thomson F; Craighead M
    Neurochem Res; 2008 Apr; 33(4):691-707. PubMed ID: 17960478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.
    Breuer ME; van Gaalen MM; Wernet W; Claessens SE; Oosting RS; Behl B; Korte SM; Schoemaker H; Gross G; Olivier B; Groenink L
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):101-6. PubMed ID: 18668225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.
    Scott LV; Dinan TG
    Life Sci; 1998; 62(22):1985-98. PubMed ID: 9627097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent increase in hypothalamic arginine vasopressin gene expression during protracted withdrawal from chronic escalating-dose cocaine in rodents.
    Zhou Y; Litvin Y; Piras AP; Pfaff DW; Kreek MJ
    Neuropsychopharmacology; 2011 Sep; 36(10):2062-75. PubMed ID: 21677651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol Drinkers.
    Katz DA; Locke C; Liu W; Zhang J; Achari R; Wesnes KA; Tracy KA
    Alcohol Clin Exp Res; 2016 Apr; 40(4):838-45. PubMed ID: 26969417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
    Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
    Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention.
    Hu H; Zarate CA; Verbalis J
    Psychiatry Clin Neurosci; 2024 Sep; 78(9):495-506. PubMed ID: 38923665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of TS-121, a novel vasopressin V
    Kamiya M; Sabia HD; Marella J; Fava M; Nemeroff CB; Umeuchi H; Iijima M; Chaki S; Nishino I
    J Psychiatr Res; 2020 Sep; 128():43-51. PubMed ID: 32521250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.